BiotechTube

Imipenem+Relebactam

ApprovedWithdrawn
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Carbapenem-Resistant Enterobacteriaceae Infection

Conditions

Carbapenem-Resistant Enterobacteriaceae Infection, KPC, Gram-Negative Bacterial Infections, Antibiotic Resistant Infection

Trial Timeline

Jun 7, 2021 → Jan 12, 2023

NCT ID
NCT04785924

About Imipenem+Relebactam

Imipenem+Relebactam is a approved stage product being developed by Merck for Carbapenem-Resistant Enterobacteriaceae Infection. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT04785924. Target conditions include Carbapenem-Resistant Enterobacteriaceae Infection, KPC, Gram-Negative Bacterial Infections.

Hype Score Breakdown

Clinical
20
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04785924ApprovedWithdrawn